Orlistat 60 mg nda 21-887 Label Comprehension Study



Download 38.65 Kb.
Date09.12.2016
Size38.65 Kb.

Orlistat 60 mg NDA 21-887 Label Comprehension Study

  • Joint Nonprescription Drugs Advisory Committee and Endocrine and Metabolic Drugs Advisory Committee Meeting
  • Bethesda, Maryland / January 23, 2006
  • Susanna Weiss, Ph.D., J.D.
  • Division of Nonprescription Clinical Evaluation
  • Office of Nonprescription Products
  • Center for Drug Evaluation and Research

Overview of the Presentation

  • Regulation concerning label comprehension
  • The purpose of label comprehension studies
  • The Orlistat label comprehension study:
    • Design, population, questions and procedures
    • Results concerning the Drug Facts label
    • Results regarding materials included inside the package

Regulation

  • 21 CFR 330.10(a)(4)(v) . . .
  • [Over-the-counter drug labels shall be written] in
  • such terms as to render them likely to be read and
  • understood by the ordinary individual, including
  • individuals of low comprehension, under
  • customary conditions of purchase and use.
  • (Low comprehension = < 8th grade reading level)
  • The Purpose of
  • Label Comprehension Studies
  • Primary Objectives
  • To measure consumers’ understanding of key label information:
  • USE
  • WARNINGS
  • WHEN USING
  • THIS PRODUCT
  • DIRECTIONS
  • OTHER
  • INFORMATION
  • Primary Objectives
  • To measure consumers’ understanding of where to locate additional information included in the package.
  • The Orlistat
  • Label Comprehension Study

Study Design and Population

  • Inclusion/Exclusion Criteria
  • Male/Female of any race/ethnicity.
  • At least 18 years of age.
  • Expressed an interest (“somewhat” or “very interested”) in weight loss.
  • Gender Breakdown
  • General Population (GP) – 36% male and 64% female.
  • Low Literacy (LL) – 39% male and 61% female.
  • Two cohorts of individuals
  • General Population of 304 subjects, 18% of which qualified as Low Literate and were also counted in Cohort #2 (the low literacy group).
  • Low Literacy group of 160 subjects, 54 of which were from the General Population group and 106 of which were specifically recruited as low literate subjects.

Scenarios and Questions

  • Diane and her friend Bev are both overweight
  • and started taking Orlistat at the same time.
  • After taking Orlistat for 4 weeks, Diane is
  • frustrated since she has not lost the same
  • amount of weight as Bev.
  • Q42: Based on the package labeling, what, if
  • anything, is the reason why Diane is not losing
  • the same amount of weight as Bev?
  • Answer:
  • The correct answer is contained in the section of the label sub-headed:
  • When using this product where it says:
  • “How much weight you lose will depend on how closely you follow the recommended diet and the Orlistat program.”

The Interviewing Script

  • All of the study participants were told that . . .
  • This was a test of the package labeling.
  • They would not be questioned about previous knowledge or commonsense but about what has been learned from reading the information in the package labeling.
  • They should respond according to the information
  • in the label.
  • They would be able to view and read all the package labeling throughout the test.
  • The study participants’ responses were coded as:
  • CORRECT
  • or
  • ACCEPTABLE
  • or
  • INCORRECT
  • Coding of Responses
  • Results

Breakdown of the Results

  • 27 scenarios and questions were used to test consumer
  • comprehension of information in the Drug Facts Label.
  • The General Population group achieved the following
  • scores by answering questions correctly or acceptably:
  • 95% to 100% on 11 scenarios
  • 90% to 94% on 4 scenarios
  • 82% to 89% on 7 scenarios
  • 72% to 79% on 3 scenarios
  • 69% on one scenario and question
  • 48% on one scenario and question
  • Drug Facts Label Communication Objective – Results
  • Reported by % of Total Correct + Acceptable Responses
  • GP% LL%
  • Product Use (“To promote weight loss in overweight adults
  • when used along with a reduced calorie and low fat diet”)
  • 100
  • 100
  • Not okay to take Orlistat if not overweight
  • 79
  • 78
  • Product Use and Target Population
  • GP = General Population group
  • LL = Low Literacy group
  • Drug Facts Label Communication Objective – Results Reported by
  • % of Total Correct + Acceptable Responses
  • GP% LL%
  • Not okay to use Orlistat if having gallbladder problem
  • 99
  • 97
  • Not okay to use Orlistat if had kidney stones in the past
  • 97
  • 97
  • Not okay to use Orlistat if currently taking medicine for diabetes
  • 97
  • 97
  • Okay to use Orlistat if experiencing problems sleeping
  • 97
  • 94
  • 97
  • 94
  • Not okay to use Orlistat if under 18 years old.
  • 96
  • 95
  • Okay to take Orlistat if not currently taking any other medication for weight loss
  • 96
  • 94
  • Not okay to use Orlistat while taking cyclosporine
  • 96
  • 90
  • Not okay to use while breastfeeding
  • 95
  • 92
  • Not okay to use Orlistat while taking Warfarin
  • 94
  • 93
  • Okay to use Orlistat if experiencing a headache
  • 92
  • 80
  • Not okay to use Orlistat if diagnosed with problems absorbing food
  • 90
  • 86
  • Okay to continue using Orlistat if experiencing loose stool and bowel changes
  • 86
  • 74
  • Warnings
  • Warnings
  • Cyclosporine
  • Warfarin
  • Kidney Stones
  • Gallbladder
  • Diabetes
  • Responses
  • GP
  • %
  • LL
  • %
  • GP
  • %
  • LL
  • %
  • GP
  • %
  • LL
  • %
  • GP
  • %
  • LL
  • %
  • GP
  • %
  • LL
  • %
  • Correct Exactly Per
  • Label Instruction
  • 91
  • 89
  • 29
  • 22
  • 59
  • 50
  • 61
  • 47
  • 45
  • 39
  • Acceptable Alternative:
  • “Not okay to use” or
  • “Ask Dr /HC Professional”
  • 5
  • 1
  • 65
  • 71
  • 38
  • 47
  • 38
  • 50
  • 52
  • 58
  • Total correct and acceptable responses
  • 96
  • 90
  • 94
  • 93
  • 97
  • 97
  • 99
  • 97
  • 97
  • 97
  • Warnings
  • The GP group achieved excellent scores on almost all label warnings.
  • The LL group achieved excellent scores on almost all label warnings.
  • For example, comprehension of warnings for cyclosporine, warfarin,
  • kidney stones, gallbladder problems, and diabetes were as follows:
  • Drug Facts Label Communication Objective – Results Reported by % of Total Correct + Acceptable Responses
  • GP% LL%
  • Change your eating patterns before starting Orlistat
  • 95
  • 86
  • How Orlistat works to promote weight loss
  • 85
  • 64
  • Timeframe of when to expect results when taking Orlistat
  • 82
  • 69
  • Why weight loss may vary between people taking Orlistat
  • 82
  • 62
  • How to decrease the likelihood of loose stool and bowel changes
  • 72
  • 48
  • Drug Facts Label Communication Objective – Results
  • Reported by % of Total Correct + Acceptable Responses
  • GP% LL%
  • Recommended dosage to start taking Orlistat
  • 93
  • 90
  • When to increase dose from 1 capsule to 2 capsules with each meal
  • 89
  • 81
  • Where to find information on using Orlistat
  • 88
  • 85
  • Maximum capsules of Orlistat in one day
  • 86
  • 67
  • Weight loss goal not met after 6 months
  • 78
  • 74
  • Directions
  • Drug Facts Label Communication Objective
  • Results Reflect Total of Correct + Acceptable Responses
  • Sponsor
  • GP% LL%
  • Reviewer
  • GP% LL%
  • Q27 – Concern about vitamin absorption
  • 93
  • 88
  • 69
  • 50
  • Q28 – Recommended timing for taking a multivitamin
  • 79
  • 66
  • 48
  • 34
  • Directions
  • The need to take a daily multivitamin and the timing for taking the multivitamin
  • Concern About Vitamin Absorption
  • Directions
  • to ensure adequate
  • vitamin absorption,
  • you should take a
  • multivitamin once a
  • day, 2 hours before or after taking orlistat
  • capsules

Concern About Vitamin Absorption

  • Q 27 Scenario
  • Terry is overweight and would like to use Orlistat
  • for weight loss. She is concerned that she will not
  • be able to absorb the vitamins in the food if she
  • starts taking Orlistat.
  • Q 27: Based on the package labeling, what, if
  • anything, should Terry do about this concern?
  • Responses Coded by Sponsor as Correct / Acceptable
  • GP
  • % (N=304)
  • LL
  • % (N=160)
  • GSK’s Total of Correct + Acceptable Responses
  • 93%
  • 88%
  • Correct
  • 69%
  • 50%
  • Take a multivitamin once a day, 2 hours before or after taking
  • Orlistat
  • 47%
  • 36%
  • Take a multivitamin
  • 21%
  • 14%
  • Take a multivitamin once daily/ Take a multivitamin
  • 1%
  • 0
  • Acceptable
  • 24%
  • 38%
  • Ask a doctor
  • Ask a doctor / pharmacist
  • Eat better foods / More balanced diet / Watch diet
  • Call 1-800#
  • Look in User’s Guide / Manual / Directions on label / Reference card
  • Q27 Concern About Vitamin Absorption
  • Partially
  • correct
  • COMPLETELY CORRECT RESPONSE

Recommended Timing for Taking a Multivitamin

  • Q 28 Scenario
  • Terry is overweight and would like to use Orlistat
  • for weight loss. She is concerned that she will
  • not be able to absorb the vitamins in the food if
  • she starts taking Orlistat.
  • Q28: Based on the package labeling, what is the
  • recommended timing for taking a multivitamin to
  • ensure adequate vitamin absorption?
  • Q28 . . . What is the recommended timing for taking a
  • multivitamin to ensure adequate vitamin absorption?
  • General Population
  • % N= 160
  • Low
  • Literacy
  • % N=102
  • GSK’s Total of Correct + Acceptable Responses
  • 79%
  • 66%
  • Correct
  • 48%
  • 34%
  • 2 hours before or 2 hours after taking capsule Correct
  • 48%
  • 34%
  • One to two hours before meals
  • 1%
  • 0%
  • Acceptable
  • 31%
  • 31%
  • 2 hours before [incomplete answer]
  • 2 hours after [incomplete answer]
  • Six months; Once a day; Once a day for six months
  • Before a meal; After you eat
  • Ask a doctor or pharmacist; Call 1-800#
  • Once a day 2 hours before [incomplete answer]
  • Due to rounding, percentages may not sum.
  • Q28 Recommended Timing for Taking a Multivitamin
  • Question 27
  • GP
  • n=304
  • LL
  • n=160
  • “Take a multivitamin once a day, 2 hours before or after taking Orlistat capsules”
  • (144)
  • 47%
  • (58)
  • 36%
  • Question 28
  • GP
  • n=160
  • LL
  • n=102
  • "2 hours before or 2 hours after taking capsule”
  • (76)
  • 48%
  • (35)
  • 34%
  • (220)
  • (93)
  • Total number of subjects who responded correctly on Q27 and Q28
  • 73%
  • 58%
  • Timing for Taking a Multivitamin
  • Target Population:
  • Orlistat is for Overweight Adults
  • Jane is 25 years old and not overweight. Jane is considering using Orlistat.
  • Q15/Q16: Based on the package labeling, is it okay or not okay for Jane to use Orlistat?
  • Orlistat is for Overweight Adults
  • Jane is 25 years old and not overweight. Jane is considering using Orlistat
  • Q15/Q16: Based on the package labeling, is it okay or not okay for Jane to use Orlistat?
  • 78% of the GP group responded correctly according to the label that
  • it is “Not okay.”
  • 74% of the LL group responded correctly according to the label that
  • it is “Not okay.”
  • 21% of the GP group responded incorrectly that it would be okay.
  • 23% of the LL group responded incorrectly that it would be okay.
  • The remaining small percentage in each group said “Jane” should
  • ask her doctor or healthcare professional.

Possible Use by Non-Overweight Adults

  • Verbatim Responses
  • Over 20% of the respondents from each cohort (GP & LL) rationalized
  • that, since “Jane” in the scenario was over 18 and healthy, and since
  • there was no specific warning on the box stating that non-overweight
  • people should not take Orlistat, it would be okay for “Jane” to take Orlistat.
  • Is not contraindicated
  • Package / label does not mention
  • Don’t have to be overweight to use
  • Over 18 years old / old enough
  • Healthy / isn’t sick
  • Safe to use

Possible Use by Non-Overweight Adults

  • Another set of responses reflected the idea that Orlistat
  • would be good for maintaining desired weight. Here are
  • some examples:
  • “It could help her not to be overweight.”
  • “If she wants to maintain her weight. It’s fine to use.”
  • “If she uses it moderately, it will help her maintain her weight.”
  • “It could help her stay thin.”
  • “She just might want to keep her weight the way it is.”
  • “It’s only a fat reducer and it would keep her thin.”
  • “Helps block fat so you don’t gain weight.”

Possible Use by Non-Overweight Adults

  • A variety of other interesting verbatim responses referred to whether or not
  • 25-year-old, non-overweight “Jane” in the scenario could take Orlistat:
  • “If she really wants to go for that [famous actress] look, she can. It doesn’t say specifically not to, and it probably won’t be any worse for her than if she just goes bulimic.”
  • “If she wants to, it could help to lose cellulite but she really doesn’t need it but she has no health problems to keep her from using the product.”
  • “Some people may want to lose weight no matter what they weigh. Nowhere on this box does it say for those that are overweight only.”
  • “She can see if it will cut down her appetite.”
  • “It just says a well-balanced diet and I don’t think it says you can’t use it unless you are overweight.”
  • “She doesn’t need to take it, but it doesn’t say not to take it if not overweight.”
  • Additional Information
  • Included in the Package
  • Q19 Based on the package labeling,
  • where could Steve find information?
  • Information on what to order when dining out.
  • Steve is overweight. He has been using Orlistat. Steve is going out
  • to dinner tonight but is not sure what would be best for him to order.
  • The accurate response is:
  • “Away from Home Guide” which clearly states that it covers “Dining Out” issues.
  • Some variations are acceptable:
  • Dining Out Guide.
  • In the little restaurant guide.
  • Calorie/fat counter/diet cards.
  • Where to Find Information in the Educational Materials
  • GP % LL %
  • Q48 Information on fast food restaurants
  • 90
  • 90
  • Q49 Information on setting realistic goals
  • 90
  • 86
  • Q51 Information on understanding personal eating habits
  • 82
  • 76
  • Q47 Information on snacking tips
  • 77
  • 69
  • Q50 Information on learning to navigate the grocery store
  • 66
  • 65
  • Q52 Information on the food and activity tracker
  • 43
  • 41
  • Q35 Information on fat and calories
  • 42
  • 26
  • Q26 Information on preparing meals
  • 42
  • 24
  • Q19 Information on what to order when dining out
  • 37
  • 23
  • Additional Information Included in the Package
  • “Ask a doctor/pharmacist” is not an acceptable answer, nor are a number of
  • other responses that were coded as “acceptable.” The following are so
  • general as to be no better than default answers:
  • In the booklet
  • In the packet
  • Inside the box
  • As many as 42 respondents gave completely inaccurate answers such as:
  • “Back of package / on back in drug facts; Directions on box / label;
  • Directions; On the label / box”
  • 4 respondents said:
  • “From restaurant / ask the waiter / restaurant / consult the restaurant”
  • Other respondents said look in the “When using this product” section of
  • the Drug Facts label; or “In the inactive ingredients” section of the
  • label; or in the “Activity Tracker;” or simply at “The bottom of the label.”
  • Where to Find Information on What to Order When Dining Out

Summary and Observations

  • There was very high comprehension of the label Warnings.
  • Correct response rates concerning cyclosporine were in the 90th percentile for both the General Population and Low Literacy cohorts.
  • Almost all the label Directions were well understood by the General Population group and the Low Literacy group.
  • Only the directions concerning multivitamin use were not particularly well understood by either group.
  • This indicates that some modification of the Drug Facts label is needed to clarify and emphasize the instructions concerning taking multivitamins.

Summary and Observations

  • The lack of a warning on the Drug Facts label specifically telling consumers “Do not use if you are not overweight,” confused some participants and led them to think that use by non-overweight individuals would be acceptable.
  • After the completion of the label comprehension study, the Sponsor amended the Drug Facts label to include a specific Warning that states: “Do not use if you are not overweight.” This may help to alleviate the misunderstanding.
  • It may help consumers to make a more informed self-selection and purchase decision if there were some indication on the external packaging as to what constitutes being overweight. From the label comprehension study it seems that many people have a variety of subjective opinions about this.

Directory: ohrms -> dockets
dockets -> Food and drug administration center for biologics evaluation and research
dockets -> Food and drug administration fda obesity working group
dockets -> This transcript has not been edited or corrected, but appears as received from the commercial transcribing service. Accordingly the Food and Drug Administration makes no representation as to its accuracy
dockets -> Food and drug administration center for biologics evaluation and research vaccines and related biological products
dockets -> Memorandum date: February 6, 2001 to: Members, Peripheral and Central Nervous Systems Drugs Advisory Committee and Invited Guests from: Staff Division of Neuropharmacological Drug Products subject: Background Document for pcns meeting of March 13
dockets -> Twenty-seventh meeting of the biological response modifiers advisory committee
dockets -> Exocrine pancreatic insufficiency drug products
dockets -> One Year Post-Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Advisory Committee Meeting June 29, 2005
dockets -> Towards a Consensus in Measuring Outcomes in New Agents for Prostate Cancer

Download 38.65 Kb.

Share with your friends:




The database is protected by copyright ©sckool.org 2020
send message

    Main page